A carregar...
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) early breast cancer (EBC) as recently demonstrated by the EBCTCTG metaanalysis on trastuzumab in HER2+ EBC: Adding trastuzumab to chemotherapy has reduced recurrence rates and breast-cancer r...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2022-03-01
|
| Colecção: | Breast |
| Assuntos: | |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S0960977622000066 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|